Table 2.
Results of Univariate Analysis Performed in All of the Patients
| Variable | Responders (n = 38) | Nonresponders (n = 59) | P Value | |
|---|---|---|---|---|
| Age (years)* | 43.92 ± 11.01 | 48.92 ± 8.94 | 0.01611 | |
| Gender | ||||
| Male | 28/38 (73.7%) | 34/59 (57.6%) | } | 0.10795 |
| Female | 10/38 (26.3%) | 25/59 (42.4%) | ||
| Body mass index* | 24.11 ± 2.73 | 25.57 ± 3.45 | 0.07827 | |
| Infected hepatocytes (%)* | 6.83 ± 4.50 | 13.44 ± 10.05 | 0.00003 | |
| Serum HCV-RNA [(IU/ml)× 106]* | 1.71 ± 2.70 | 1.32 ± 1.86 | 0.40694 | |
| ALT (IU/L)* | 114.66 ± 107.37 | 105.31 ± 58.61 | 0.48027 | |
| AST (IU/L)* | 70.29 ± 70.98 | 72.97 ± 37.76 | 0.80948 | |
| GGTP (IU/L)† | 30 (11–239) | 43 (9–326) | 0.01856 | |
| Ferritin (ng/ml)† | 216 (41–1250) | 132 (6–1122) | 0.34071 | |
| Iron (μg/dl)* | 128.27 ± 57.45 | 133.18 ± 56.98 | 0.72552 | |
| Necroinflammatory activity† | 4 (1–6) | 4 (1–7) | 0.60170 | |
| Fibrosis score† | 2 (0–4) | 2 (0–4) | 0.53835 | |
| Previous treatment | ||||
| Yes | 14/38 (36.8%) | 35/59 (59.3%) | } | 0.03065 |
| No | 24/38 (63.2%) | 24/59 (40.7%) |
Statistically significant P values are highlighted in boldface.
AST, aspartate aminotransferase.
*
Expressed as the mean ± SD.
†
Expressed as the median (range).